FutureONCOLOGYPlain Language Summary of PublicationPlain language summary and patientperspective of the American Society forClinical Oncology guideline:managementof stage 3 non-small-cell lung cancerRachel Jenkins",Joanne Walker and Upal Basu Roy3Future Science Group,London,UK Becaris Publishing Ltd,Royston,UK:LUNGevity Foundation,Chicago,IL USA*Author for correspondenceFirst draft submitted:5 December 2022:Accepted for publication:17 February 2023:Published online:20 March 2023SummaryHow to say(double click sound iconWhat is this summary about?to play sound)..This is a plain language summary of a guideline on the managementof stage 3 non-small-cell lung cancer,also known as NSCLC.This.Adjuvant:A-joo-vuntguideline was written by the American Society for Clinical Oncology(ASCO.Neoadjuvant:NEE-oh-A-joo-vantfor short)and published in the Journal of Clinical Oncology..Osimertinib:OH-sih-MER-tih-nibWhy were the guidelines developed?.Durvalumab:dur-VAL-yoo-mabThe purpose of the ASCO guideline is to provide recommendations·AsCo:AZ-Koh)to healthcare professionals in the US including oncologists,surgeons,pathologists,radiologists,and nurses on how best to diagnose and treatPronunciation taken from the National CancerInstitute Dictionary of Cancer Termspeople with stage 3 NSCLC.How were the guildeines developed?The ASCO quideline is based on the latest research and scientific evidence to make certain the recommendations are up todate and based on reliable data and best practice.In 2021,a group of experts were asked by ASCO to form an Expert Panel.The Expert Panel reviewed the results of 127 clinical research studies on NSCLC that were done between 1990 and 2021.They looked at how NSCLC had been diagnosed and treated in these studies,as well as at patients'survival and quality oflife.The Expert Panel used these findings and their own expertise to form their recommendations and produce the 2021ASCO Guideline called'Management of Stage 3 Non-Small-Cell Lung Cancer:ASCO Guideline.What information does the guideline contain?The guideline aims to answer the following questions:What are the most precise ways to confirm and stage.Which patients who can be treated with surgery couldNSCLC in people suspected of having a stage 3 disease?also have an additional treatment after their surgery?Which patients with stage 3 NSCLC can be treated most.Which treatment and/or management is most suitablesuccessfully with surgery?for patients who cannot have surgery?Which patients who can be treated with surgery couldalso have an additional therapy before their surgery?Where can I find the original article on which this summary is based?You can read the original article published for free at the link below:https://ascopubs.org/doi/full/10.1200/JCO.21.02528FutureMedicine Paort of102217/fon-2022-1212g2023 The AuthorsFuture Oncol.(Epub ahead of print)t5SN1479-6694
